MedPage Today (9/11, DePeau-Wilson) reports, “Every-six-month dosing of the long-acting injectable paliperidone palmitate (Invega Hafyera) for schizophrenia was effective and safe up to three years, researchers reported” in “an intention-to-treat analysis that included 121 patients.” The study revealed that “95.9% on the twice-a-year dose of the atypical antipsychotic remained relapse-free.” The findings were presented in a poster at Psych Congress 2023.
Related Links:
— MedPage Today (requires login and subscription)